Betalin Therapeutics

What Betalin Therapeutics does

Betalin Therapeutics is a privately held, clinical-stage biotechnology company developing an Engineered Micro-Pancreas (EMP), a cell therapy intended to treat insulin-dependent diabetes by restoring endogenous insulin secretion. Founded in 2015 and headquartered in Ramat Gan, Israel, the company is built around a proprietary biological platform that combines pancreatic islet cells with a custom scaffold designed to support cell survival, vascularization, and function after transplantation, with the goal of eliminating or reducing the need for exogenous insulin and chronic immunosuppression.

The company operates with a 1-10 person team and has disclosed approximately $5.75M in cumulative funding across rounds between 2017 and 2022. The European Innovation Council has been the dominant disclosed capital source, including the largest single tranche of $2,639,638 in March 2020, supplemented by EISMEA non-dilutive funding and a $2.5M round in April 2019. The leadership team consists of founders Shuki Joshua Hershcovich and Shay Hershcovich, with Avi Treves serving as CSO.

Betalin has no commercial revenue, pricing model, distribution channels, or named customers in the disclosed data. Its business model is consistent with a pre-clinical/early-clinical cell therapy venture: capital is raised in tranches to fund R&D, regulatory, and eventual clinical activities, with monetization expected to come either through out-licensing, partnership, or eventual product commercialization once the EMP reaches regulatory approval. No manufacturing, partnership, or licensing deals are documented in the input.

Name

Betalin Therapeutics

Website

https://betalintherapeutics.com

Company type

Private

Founded year

2015

Headcount range

1–10 employees

Short description

Betalin Therapeutics is an Israel-based clinical-stage cell therapy company developing an Engineered Micro-Pancreas (EMP) — islet cells combined with a proprietary scaffold — for insulin-dependent diabetes patients.

Ownership category

akta.pro rank

Product category

Cell Therapy

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors) (HLAAAAAI)

akta.pro secondary industry

Type 1 Diabetes Care (HLAKADAB)

Keywords

• Cell therapy diabetes
• Engineered micro-pancreas
• Regenerative medicine
• Insulin-dependent treatment
• Biomedical tissue engineering

Headquarters

HQ city

Ramat Gan

HQ country

Israel

HQ region

Middle East

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Core offering

Betalin Therapeutics develops the Engineered Micro-Pancreas (EMP), a cell therapy solution designed to treat insulin-dependent diabetes. The company combines biological scaffolds with insulin-producing cells to create an implantable therapeutic that aims to restore natural insulin regulation in diabetic patients.

Differentiator

Problem solved

Functional benefit

Products and services

• Engineered Micro-Pancreas (EMP)

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves5 records

Expansion highlights3 records

Direct peers

• ViaCyte: ViaCyte develops stem cell-derived islet replacement therapies for insulin-dependent diabetes. It is the most directly comparable cell-therapy-for-T1D peer to Betalin's engineered micro-pancreas approach.
• Sigilon Therapeutics: Sigilon is developing encapsulated cell therapies (including for diabetes) using its Afibromer platform, conceptually adjacent to Betalin's engineered micro-pancreas cell encapsulation approach.

Broad incumbents

• Vertex Pharmaceuticals: Vertex acquired Semma Therapeutics and is clinically advancing VX-880, an islet cell therapy for type 1 diabetes. It is a much larger incumbent whose cell-therapy program directly competes with Betalin's therapeutic concept.
• Novo Nordisk: Novo Nordisk is the dominant diabetes incumbent (insulin, GLP-1) and is investing in stem cell-derived islet therapies, making it both a competitive threat and a potential acquirer of Betalin-style cell-therapy assets.
• Eli Lilly: Eli Lilly is a major diabetes franchise incumbent (insulin, Mounjaro/Zepbound) and a relevant comparator for strategic positioning and potential partnership or M&A interest in cell-therapy assets.
• Sanofi: Sanofi maintains a significant diabetes portfolio (Lantus, Toujeo) and has expressed interest in advanced diabetes therapeutics, making it a relevant incumbent peer for partnership and competitive dynamics.

Emerging players

• Seraxis: Seraxis is developing stem cell-derived islet cell therapies for insulin-dependent diabetes, representing a smaller, more focused competitor in the same cell-therapy-for-T1D category.
• Sernova: Sernova is developing its Cell Pouch system with stem cell-derived islets for type 1 diabetes, overlapping with Betalin's engineered micro-pancreas concept of a scaffolded cell-therapy platform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

• Facebookfacebook.com/betalin.therapeutics.inc
• LinkedInlinkedin.com/company/betalin-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Betalin Therapeutics